Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it.
Stanford Medicine breast surgeons are the first in the country to use a new technology that lights up cancer cells left behind when a tumor is removed.
“Cold” tumors are resistant to common immunotherapies. Stanford Medicine researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.
Stanford Medicine researchers have created a liquid biopsy test capable of detecting cancers, molecular mechanisms of resistance to treatment and tissue injury.
HPV-related head and neck cancers are rising. Vaccination, advances like robotic surgery, and personalized care are improving prevention and treatment outcomes.
The Stanford Medicine physician, who is using his diagnosis to teach about never-smoker lung cancer, will be the keynote speaker at the School of Medicine’s graduation ceremony.
Uri Ladabaum, MD, MS, discussed current colorectal cancer screening recommendations and how screening tests may evolve to be more accurate and convenient.
Stanford Medicine scientists are using artificial intelligence to better capture how healthy cells surrounding tumors influence cancer cell behavior and how those interactions can inform treatments.
Stanford Medicine’s Minimally Invasive MR Interventional Center employs two kinds of therapy for treating prostate cancer without surgery, radiation or chemotherapy.
Stanford Medicine researchers sifted through thousands of single nucleotide mutations in DNA to identify fewer than 400 that are functionally associated with inherited cancer risk.
Stanford Medicine-led research found that only one-third of women who pause hormone therapy to become pregnant resumed treatment and that the rates of recurrence in this population were doubled.
Breast cancers at all stages are defined by the structure of their genomes, Stanford Medicine researchers find. Targeting these processes early is likely to offer unexpected therapeutic avenues.
Stanford treated its first patient with Tecelra, a breakthrough engineered T cell receptor therapy that uses a patient’s own immune cells to target cancer.
Cancer research is being redefined by trained patient advocates who ensure patient voices guide treatment, trials, and outcomes for better care and equity.
The new issue of Stanford Medicine magazine includes articles on innovative cancer care and research, discoveries about its mechanisms, and experiencing cancer as a physician.
A new artificial intelligence tool developed at Stanford Medicine combines data from medical images with text to predict cancer prognoses and treatment responses.
Researchers used a new screening technique to identify genes involved in heart cell damage during a common chemotherapy treatment. They also found a drug that may be able to prevent it.
CAR-T cells show promise against pediatric diffuse midline gliomas, brain and spinal cord tumors that are among the deadliest cancers, a Stanford Medicine trial found.
Tiny circles called ecDNA are critical in cancer development and drug resistance. An international Stanford Medicine-led team publishes landmark studies detailing new findings and potential therapies.
Blood tests for colorectal cancer are an option for patients who would otherwise not be screened, but they are not as effective as colonoscopies or stool tests, a Stanford Medicine-led study found.
Allison Kurian and Jennifer Caswell-Jin received a $3.5 million legacy gift to launch the Bright Pink Preventive Risk Outreach And Cascade Testing Program.
The SCI offers robust support to students, residents, fellows, and junior faculty to educate and prepare them to address the challenges in their field.
The field of spatial biology holds promise in helping scientists gain an in-depth understanding of the tumor microenvironment to predict patient outcomes.
In an early Stanford Medicine study, CAR-T cell therapy helps some with intractable lymphoma, but those who relapse have few options. Modifying the therapy's molecular target improved response.
TRACeR platforms more accurately recognize a wide variety of surface proteins expressed by cancer cells that make them easier to target with the body’s own immune system.
Researchers used artificial intelligence to predict the activity of thousands of genes in tumors based on routinely collected images of tumor biopsies. It could guide treatment without costly genomic tests.
A longtime caretaker of very ill patients, clinical professor, Bryant Lin, MD, a primary care physician, educator and researcher, is now discovering what it's like to be on the opposite end of that arrangement.
The Office of Communication & Public Affairs is dedicated to sharing School of Medicine news with the media and helping journalists secure expert interviews, photographs and rich media for stories on medicine and health care.
